BOD

Patrick Verheyen

Mr. Verheyen had a distinguished 35-year career with Janssen Pharmaceutical Companies of Johnson & Johnson where he held positions of growing responsibility until his retirement as Global Head, Janssen Business Development in 2021. During his time there he led Janssen’s Business Development organization to identify, execute, integrate and manage global licensing, mergers & acquisitions (M&A), divestiture and out-licensing deals across Janssen’s therapeutic areas of focus. Mr. Verheyen led the 2017 $30B acquisition of Actelion, which established Janssen’s footprint in the Pulmonary Hypertension space, and the 2020 $6.5B acquisition of Momenta Pharmaceuticals, which broadened Janssen’s pipeline in autoimmune diseases. During this time, Mr. Verheyen also served as a member of the Pharmaceuticals Group Operating Committee. Additionally, he played a key role in the 2009 $1B Cougar Biotech acquisition that significantly enhanced Janssen’s portfolio in prostate cancer treatment. During his career, Mr. Verheyen helped design and launch Johnson & Johnson Innovation, established its presence in Boston and Shanghai and led the Johnson & Johnson Innovation team in London. The creation of Johnson & Johnson Innovation significantly increased the ability of Johnson & Johnson to globally connect with the most cutting-edge science and technology. Mr. Verheyen earned his master’s degree in bioengineering at the University of Leuven, Flanders, Belgium.